These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.
    Author: Ceraudo E, Tan YV, Nicole P, Couvineau A, Laburthe M.
    Journal: J Mol Neurosci; 2008 Nov; 36(1-3):245-8. PubMed ID: 18597186.
    Abstract:
    Vasoactive intestinal peptide (VIP) is a widespread neuropeptide, which exerts many biological functions through interaction with the VPAC1 receptor, a class II G protein-coupled receptor. Photoaffinity labeling studies combined with 3D molecular modeling demonstrated that the central and C-terminal parts of VIP (segment 6-28) have physical contacts with the N-terminal ectodomain (N-Ted) of VPAC1 receptor. However, the domain of the hVPAC1 receptor interacting with the N-terminus of VIP (1-5) is still unknown. We have synthesized a photoreactive probe Bpa0-VIP. After photolabeling and receptor cleavage, Nu-PAGE analysis revealed a 5-kDa labeled fragment corresponding to the 130-137 sequence of hVPAC1 receptor, indicating that the N-terminus of VIP also interacts with the N-ted. A photoreactive probe, Bpa0-PG97-269, was also synthesized with the specific peptide antagonist PG97-269. After photoaffinity labeling, a glycosylated 15-kDa fragment is identified by cyanogen bromide (CNBr) cleavage and corresponds to the 43-66 sequence of the hVPAC1 receptor N-ted. These results indicate that: (1) the N-terminal part of VIP physically interacts with the N-ted in the continuity of 6-28 VIP sequence; (2) the N-terminal part of VIP and the selective peptide antagonist (PG97-269) have different sites of interaction with the VPAC1 receptor N-ted.
    [Abstract] [Full Text] [Related] [New Search]